STAT+: The Shortage of Many Medicines in the U.S. Remains a ‘Systemic’ Problem, a New Analysis Finds

Why It Matters

Prolonged drug shortages strain patient care, inflate costs, and expose vulnerabilities in the pharmaceutical supply chain, prompting urgent regulatory and industry action.

Key Takeaways

• 2025 shortages fell 23% to lowest level since 2017.
• Average shortage length grew to 5.3 years, up from 4.3 years.
• 66% of shortages persisted over three years.
• 39% of drugs unavailable for more than five years.
• 75 drugs spanned 130 therapeutic categories, showing broad impact.

Pulse Analysis

The latest U.S. Pharmacopeia analysis paints a paradoxical picture: while the count of drug shortages has declined for a second year, the duration of each shortage is lengthening. This trend reflects deep‑seated supply‑chain fragilities, including reliance on a handful of overseas manufacturers, limited redundancy in production capacity, and regulatory bottlenecks that delay new facilities from entering the market. As manufacturers consolidate and older plants retire, the remaining sources become choke points, turning temporary glitches into multi‑year scarcities.

For patients and providers, the ramifications are immediate and costly. Extended shortages force clinicians to substitute less‑optimal therapies, potentially compromising treatment efficacy and increasing adverse‑event risk. Hospitals incur higher inventory costs as they stockpile alternatives, while insurers grapple with price spikes for substitute drugs. The breadth of affected therapeutics—spanning oncology, cardiology, infectious disease, and rare‑disease treatments—means that no specialty is insulated, amplifying the overall burden on the healthcare system.

Policymakers and industry leaders are now confronting the need for systemic reforms. Proposals include expanding FDA’s fast‑track pathways for critical drug manufacturing, offering tax incentives for domestic production, and mandating greater transparency around supply‑chain risk. Collaborative initiatives, such as public‑private consortia to map vulnerability hotspots, aim to build redundancy before shortages become entrenched. Without decisive action, the United States risks a chronic drug‑supply crisis that could erode patient outcomes and inflate healthcare expenditures for years to come.